# **Special Issue**

# Application of Gastrointestinal Peptides in Medicine

# Message from the Guest Editors

Conceptually, a wide beneficial effect, both peripherally and centrally, might have been essential for the harmony and function of the gut-brain axes. From the original viewpoint of gut peptides' significance and brain relation, these could be favorable behavioral findings (interaction with main systems; anxiolytic, anticonvulsive and antidepressant effects; counteracted catalepsy). Further applications are possible in muscle healing and function recovery, both peripherally and centrally mediated muscles disabilities, heart failure including arrhythmias and thrombosis, and smooth muscle function recovery. Finally, encephalopathies, acting simultaneously in both the peripheral and central nervous system, and large lesions in the brain and peripheral organs, can be targets for gut peptide therapy. Severe blood pressure disturbances (i.e., venous (intracranial hypertension, portal and caval hypertension) and arterial (i.e., aortal hypotension or hypertension)) can be targeted by gut peptide therapy. The existence of a multimodal axis in healing as a function of the brain-gut axis and the gut-brain axis as a whole should be revealed by gut peptide therapy.

## **Guest Editors**

Prof. Dr. Predrag Sikirić

Prof. Dr. Sven Seiwerth

Dr. Anita Škrtić

# Deadline for manuscript submissions

closed (20 July 2025)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/193806

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





# **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

